A novel phenotype-based approach for systematically screening antiproliferation metallodrugs

Chemico-Biological Interactions

Volumn 182, Issue 1, 2009, Pages 84-91

  Wang, Yun Hsin ^a   Cheng, Chien Chung ^b   Lee, Wen Jie ^a   Chiou, Min Lun ^b   Pai, Chiung Wen ^a   Wen, Chi Chung ^a   Chen, Wei Li ^a   Chen, Yau Hung ^a  

^a TAMKANG UNIVERSITY   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cisplatin; Fin; Metallodrug; Proliferation; Ruthenium

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN P53; RUTHENIUM COMPLEX;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; HEPATOMA CELL; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYME CELL; MICROSCOPY; NICK END LABELING; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZEBRA FISH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; EMBRYO, NONMAMMALIAN; HUMANS; LIVER NEOPLASMS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, INTERFERENCE; NF-KAPPA B; ORGANOMETALLIC COMPOUNDS; PHENOTYPE; RUTHENIUM; TUMOR SUPPRESSOR PROTEIN P53; ZEBRAFISH;

DANIO RERIO;

EID: 70349551597     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.08.005     Document Type: Article

References (23)

1. Alderden R.A., Hall M.D., and Hambley T.W. The discovery and development of cisplatin. J. Chem. Educ. 83 (2006) 728-734
2. Zhang C.X., and Lippard S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 7 (2003) 481-489
3. Rosenberg B. Nucleic Acid-Metal Ion Interactions (1980), John Wiley & Sons Press, New York
4. Clarke M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev. 236 (2003) 209-233
5. Brabec V., and Nováková O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist. Updates 9 (2006) 111-122
6. Galanski M., Arion V.B., Jakupec M.A., and Keppler B.K. Recent developments in the field of tumor-inhibiting metal complexes. Curr. Pharm. Des. 9 (2003) 2078-2089
7. + with DNA: a potential ruthenium-based anti-cancer drug. J. Chin. Chem. Soc. 47 (2000) 213-220
8. Gaiddon C., Jeannequin P., Bischoff P., Pfeffer M., Sirlin C., and Loeffler J.P. Ruthenium(II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J. Pharmacol. Exp. Ther. 315 (2005) 1403-1411
9. Kapitza S., Jakupec M.A., Uhl M., Keppler B.K., and Marian B. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 226 (2005) 115-121
10. Zon L.I., and Peterson R.T. In vivo drug discovery in the zebrafish. Nat. Rev. 4 (2005) 35-44
11. Perner B., Englert C., and Bollig F. The Wilms tumor genes wt1a and wt1b control different steps during formation of the zebrafish pronephros. Dev. Biol. 309 (2007) 87-96
12. Kimmel C., Ballard W.W., Kimmel S.R., Ullmann B., and Schilling T.F. Stages of embryonic development in the zebrafish. Dev. Dyn. 203 (1995) 253-310
13. Westerfield M. The Zebrafish Book (2000), University of Oregon Press, Eugene, OR
14. Tsay H.J., Wang Y.H., Chen W.L., Huang M.Y., and Chen Y.H. Treatment with sodium benzoate leads to malformation of zebrafish larvae. Neurotoxicol. Teratol. 29 (2007) 562-569
15. Chen Y.H., Huang Y.H., Wen C.C., Wang Y.H., Chen W.L., Chen L.C., and Tsay H.J. Movement disorder and neuromuscular change in zebrafish embryos after exposure to caffeine. Neurotoxicol. Teratol. 30 (2008) 440-447
16. Wang Y.H., Wen C.C., Yang Z.S., Cheng C.C., Tsai J.N., Ku C.C., Wu H.J., and Chen Y.H. Development of a whole-organism model to screen new compounds for sun protection. Mar. Biotechnol. 11 (2009) 419-429
17. Chen Y.H., Wang Y.H., Chang M.Y., Lin C.Y., Weng C.W., Westerfield M., and Tsai H.J. Multiple upstream modules regulate zebrafish myf5 expression. BMC Dev. Biol. 7 (2007) 1
18. Wang Y.H., Chen Y.H., Lin Y.J., and Tsai H.J. Spatiotemporal expression of zebrafish keratin 18 during early embryogenesis and the establishment of a keratin 18:RFP transgenic line. Gene Expr. Patterns 6 (2006) 335-339
19. Wang Y.H., Chen Y.H., Lin Y.J., Wu T.N., and Tsai H.J. A keratin 18 transgenic zebrafish Tg(k18(2.9):RFP) treated with inorganic arsenite reveals visible overproliferation of epithelial cells. Toxicol. Lett. 163 (2006) 191-197
20. Chen Y.H., Lin Y.T., and Lee G.H. Novel and unexpected functions of zebrafish CCAAT box binding transcription factor (NF-Y) B subunit during cartilages development. Bone 44 (2009) 777-784
21. Shimamura K., Miyamoto Y., Kitazawa H., Kobayashi T., Kotani H., and Tokita S. High-throughput assay for long chain fatty acyl-CoA elongase using homogeneous scintillation proximity format. Assay Drug Dev. Technol. 7 (2009) 124-132
22. Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I., Bondanza S., Ponzin D., McKeon F., and De Luca M. p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3156-3161
23. Hayward R.L., Schornagel Q.C., Tente R., Macpherson J.S., Aird R.E., Guichard S., Habtemariam A., Sadler P., and Jodrell D.I. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175. Cancer Chemother. Pharmacol. 55 (2005) 577-583